Jul 15, 2026 01:29PM
Jul 15, 2026 10:18AM
Jul 15, 2026 09:51AM
Jul 15, 2026 09:21AM
Jul 14, 2026 11:15AM
Jul 13, 2026 05:37PM
Jul 13, 2026 05:36PM FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Jul 13, 2026 04:00AM
Jul 12, 2026 11:15AM
Jun 29, 2026 07:30AM
May 21, 2026 10:23AM
May 20, 2026 08:08AM
Apr 21, 2026 08:37AM
Apr 21, 2026 06:52AM Merck & Co., Inc., Rahway, NJ, USA and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC
Apr 9, 2026 08:00AM
Mar 27, 2026 08:50AM
Mar 27, 2026 06:14AM
Mar 27, 2026 04:19AM
Mar 22, 2026 09:19PM
Mar 20, 2026 12:13PM
Mar 20, 2026 12:05PM Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026
Mar 10, 2026 10:07PM
Mar 10, 2026 07:30PM
Mar 1, 2026 06:49PM
Feb 9, 2026 10:34PM
Feb 6, 2026 01:04AM
Feb 5, 2026 08:31PM
Jan 25, 2026 11:52PM FDA accepts Eisai's LEQEMBI IQLIK application for priority review
Jan 25, 2026 08:37PM
Jan 25, 2026 06:30PM
Jan 25, 2026 06:30PM
Jan 12, 2026 06:50PM
Jan 5, 2026 07:43PM
Dec 3, 2025 06:10PM
Dec 2, 2025 04:40PM New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
Dec 1, 2025 07:35PM
Nov 26, 2025 06:03AM
Nov 26, 2025 04:42AM
Nov 25, 2025 07:31AM
Nov 25, 2025 07:30AM
Nov 18, 2025 08:00AM
Nov 17, 2025 07:08AM "LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
Nov 3, 2025 08:08AM
Oct 27, 2025 12:23AM
Oct 14, 2025 03:54AM
Oct 13, 2025 07:30PM
Oct 6, 2025 04:30PM
Oct 3, 2025 04:01AM
Oct 2, 2025 08:08AM Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775
Sep 28, 2025 08:33PM

327,105 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All